You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 16, October 27, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (20)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

CSF Leptin Levels After Exogenous Administration of Recombinant Methionyl Human Leptin

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The protein hormone leptin appears to act as an afferent signal from adipose tissue to the brain indicating the state of energy reserves.1 Both serum and cerebrospinal fluid (CSF) leptin concentrations increase with body fat2; however, CSF concentrations are generally 2 orders of magnitude lower than serum concentrations. The transport of leptin across the blood-brain barrier appears to occur via a saturable system, as has been demonstrated in mice.3 This suggests a mechanism by which obese people can be "resistant" to their higher circulating levels of leptin2 and suggests that exogenous administration of leptin to treat obesity might be ineffective.2 Results of a double-blind clinical trial demonstrated that exogenous leptin (daily bolus subcutaneous injections of up to 0.3 mg/kg) has a biologic effect.4 We report here data from a separate cohort of this clinical trial indicating that recombinant leptin enters the CSF.

Methods

Six obese but otherwise . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brain Uptake of Intranasally Applied Radioiodinated Leptin in Wistar Rats
Fliedner et al.
Endocrinology 2006;147:2088-2094.
ABSTRACT | FULL TEXT  

Apoptotic Pathways Are Inhibited by Leptin Receptor Activation in Neutrophils
Bruno et al.
J. Immunol. 2005;174:8090-8096.
ABSTRACT | FULL TEXT  

Leptin Indirectly Activates Human Neutrophils via Induction of TNF-{alpha}
Zarkesh-Esfahani et al.
J. Immunol. 2004;172:1809-1814.
ABSTRACT | FULL TEXT  

Positron Emission Tomography Shows that Intrathecal Leptin Reaches the Hypothalamus in Baboons
McCarthy et al.
J. Pharmacol. Exp. Ther. 2002;301:878-883.
ABSTRACT | FULL TEXT  

High-Dose Leptin Activates Human Leukocytes Via Receptor Expression on Monocytes
Zarkesh-Esfahani et al.
J. Immunol. 2001;167:4593-4599.
ABSTRACT | FULL TEXT  

Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men
Westerterp-Plantenga et al.
Am. J. Clin. Nutr. 2001;74:426-434.
ABSTRACT | FULL TEXT  

Leptin as a Therapeutic Agent--Trials and Tribulations
Mantzoros and Flier
J. Clin. Endocrinol. Metab. 2000;85:4000-4002.
FULL TEXT  

Recombinant Leptin for Weight Loss in Obese and Lean Adults: A Randomized, Controlled, Dose-Escalation Trial
Heymsfield et al.
JAMA 1999;282:1568-1575.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.